Drug Wholesale Licences
Business Registration Certificate
Drugs Import Licenses
+86 14716233633
+852 23843951
Monday to Friday:9:30-18:30
Unit 10A, 4th Floor, Tower A, Hung Hom Commercial Center, 39 Ma Tau Wai Road, Kowloon, Hong Kong
info@ghitai.com
Home
About Ghitai
Certificate
Drug Wholesale Licences
Business Registration Certificate
Drugs Import Licenses
Drugs
Anticancer
Hepatitis C
Anti-AIDS drugs
Other
News
Contact Us
中文
中文
CONTACT US
Home
About Ghitai
Certificate
Drug Wholesale Licences
Business Registration Certificate
Drugs Import Licenses
Drugs
Anticancer
Hepatitis C
Anti-AIDS drugs
Other
News
Contact Us
中文
Medicalist Archive Posts
Medicalist
Archive
Home
Products
Anticancer
Lung Cancer
Showing 1–15 of 16 results
Lung Cancer
RETEVMO-SELPERCATINIB
Lung Cancer
LORVIQUA/LORLATINIB
Anticancer
IMFINZI/DURVALUMAB
Lung Cancer
ZYKADIA/CERITINIB
Anticancer
XALKORI/CRIZALK/CRIZOTINIB
uncategorized
TECENTRIQ/ATEZOLIZUMAB
Lung Cancer
TAGRISSO/OSIMERTINIB
Lung Cancer
TAFINLAR/DABRAFENIB
Anticancer
OPDIVO/NIVOLUMAB
Lung Cancer
MEKINIST/TRAMETINIB
Anticancer
KEYTRUDA/PEMBROLIZUMAB
Lung Cancer
GIOTRIF/AFATINIB
uncategorized
CYRAMZA/RAMUCIRUMAB
Lung Cancer
ALUNBRIG/BRIGATINIB
Lung Cancer
ALECENSA/ALECTINIB
PREV
1
2
NEXT
Search For Information About A Drug
Search for:
Drug Categories
Anti-AIDS drugs
Anticancer
Bladder cancer
Blood cancer
Breast cancer
Cervical cancer
Colorectal Cancer
Gastric cancer
Kidney Cancer
Liver cancer
Lung Cancer
Lymphoma
Melanoma
Myeloma
Ovarian Cancer
Peritoneal cancer
Prostate cancer
Thyroid cancer
Hepatitis C
uncategorized
The
recent news
June 25, 2024
Fruquintinib Wins European Approval for Pretreated mCRC
June 24, 2024
FDA Approves Adagrasib Plus Cetuximab for KRAS G12C–Mutant CRC
June 23, 2024
Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis
June 21, 2024
Emavusertib Monotherapy Shows Antitumor Activity, Safety in Select R/R AML and High-Risk MDS
June 20, 2024
Enfortumab Vedotin-ejfv(Padcev): Mechanism, Efficacy, and Administration in Urothelial Carcinoma Therapy
June 19, 2024
Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma
WhatsApp
14716233633